Although the world of radiopharmaceuticals is unknown to most, there are many parallels that can be drawn to the world of biopharmaceuticals, as Amanda Donovan can attest to. Amanda completed her PhD in Organic Chemistry at McMaster University. She is currently working as the senior director of Upstream Development at Curium Pharma. She has been working in the field of radiopharmaceuticals for 15 years and has experience in the development of parenteral drug products (diagnostic and therapeutic) as well as active pharmaceutical ingredients and medical devices. She has significant experience in both process and formulation development and in recent years she has been a key contributor and author of FDA narratives contributing to the approval of three drug products and one investigational new drug and several drug master files.